Atara Biotherapeutics (ATRA) Cash from Operations (2013 - 2026)
Atara Biotherapeutics (ATRA) posted Cash from Operations of 3073000.0 for Q1 2026, up 46.06% on a QoQ basis from 5697000.0 in Q4 2025, and up 89.08% year-over-year from 1625248.09 in Q1 2025.
Atara Biotherapeutics (ATRA) Cash from Operations (2013 - 2026) Analysis & Trends
Atara Biotherapeutics' Cash from Operations history runs 14 years deep, the most recent figure standing at 3073000.0 for Q1 2026.
- Quarterly Cash from Operations rose 89.08% year-over-year to 3073000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 25875000.0 (up 61.52% YoY) and the FY2025 annual result came in at 50940000.0, up 25.87% from the prior year.
- Cash from Operations was 3073000.0 for Q1 2026 at Atara Biotherapeutics, up from 5697000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 3073000.0 in Q1 2026 and bottomed at 84529000.0 in Q1 2022.
- A 5-year average of 34478647.06 and a median of 29612000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations soared 92.23% — and 2025, when it plunged 145.35%.
- Atara Biotherapeutics' Cash from Operations stood at 56880000.0 in 2022, then rose by 11.38% to 50406000.0 in 2023, then jumped by 51.45% to 24471000.0 in 2024, then surged by 76.72% to 5697000.0 in 2025, then soared by 46.06% to 3073000.0 in 2026.
- Business Quant data shows ATRA's Cash from Operations at 3073000.0 in Q1 2026, 5697000.0 in Q4 2025, and 9787000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 201.34 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -354.17 Mn |
| 10 | Atara Biotherapeutics | 110.04 Mn | 101.68 Mn | 392,000.00 | -3.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.07 Mn |
| Mar 31, 2026 | -3.07 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Sep 30, 2025 | -9.79 Mn |
| Sep 30, 2025 | -9.79 Mn |
| Jun 30, 2025 | -7.32 Mn |
| Jun 30, 2025 | -7.32 Mn |
| Mar 31, 2025 | -28.14 Mn |
| Mar 31, 2025 | -28.14 Mn |
| Dec 31, 2024 | -24.47 Mn |
| Dec 31, 2024 | -24.47 Mn |
| Sep 30, 2024 | -3.99 Mn |
| Sep 30, 2024 | -3.99 Mn |
| Jun 30, 2024 | -10.65 Mn |
| Jun 30, 2024 | -10.65 Mn |
| Mar 31, 2024 | -29.61 Mn |
| Mar 31, 2024 | -29.61 Mn |
| Dec 31, 2023 | -50.41 Mn |
| Dec 31, 2023 | -50.41 Mn |